Eric Swayze - Feb 3, 2023 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP Research
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze
Stock symbol: IONS
Transactions as of: Feb 3, 2023
Transactions value $: -$74,031
Form type: 4
Date filed: 2/7/2023, 04:37 PM
Previous filing: Jan 19, 2023
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IONS	Common Stock	Award	$0	+3.72K	+12.37%	$0.00	33.8K	Feb 3, 2023	Direct	F1
transaction	IONS	Common Stock	Sale	-$74K	-1.82K	-5.38%	$40.79	31.9K	Feb 6, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.52 to $40.90 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Content

Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.52 to $40.90 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.